Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer research"
DOI: 10.1158/0008-5472.can-18-0040
Abstract: Programmed death-ligand 1 (PD-L1) is a well-known immune checkpoint protein that helps cancer cells evade immune response. Anti-PD-L1 immune therapy has been approved for the treatment of several advanced human cancers. Therefore, further understanding of… read more here.
Keywords: juxtacrine signaling; immunity; expression; cancer ... See more keywords